Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant E7 TCR T Cell Therapy for HPV+ Oropharyngeal Cancer
NCT04044950Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Jul 2019
- Primary completion
- Sep 2020
- Countries
- 1
01
Overview
A Phase 2 trial of KITE-439 in oropharyngeal squamous cell carcinoma (OPSCC), sponsored by National Cancer Institute. Planned start Jul 2019; status: withdrawn.
02
Drugs
KITE-439
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT04044950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04044950.